To the Editor: Published clinical trial reports
often fail to adequately document safety findings.1
In this respect, Dr Rowbotham and colleagues2
should be commended for providing detailed safety data in their study on the
use of gabapentin for the treatment of postherpetic neuralgia.
Colman E, Stadel BV. Gabapentin for Postherpetic Neuralgia. JAMA. 1999;282(2):134-135. doi:10-1001/pubs.JAMA-ISSN-0098-7484-282-2-jbk0714